
Number of publications published per year by Gramantieri, Laura. (Source : PubMed)

Distribution of publications types for Gramantieri, Laura. (Source : PubMed)
(a publication can be of different types, so total may exceed publications count)

MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality.
Clin. Cancer Res.
2009;15;16

MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells.
Cancer Res.
2009;69;14
Selective ablation of Notch3 in HCC enhances doxorubicin's death promoting effect by a p53 dependent mechanism.
J. Hepatol.
2009;50;5
MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma.
Oncogene
2008;27;43

Human hepatocellular carcinoma expresses specific PCNA isoforms: an in vivo and in vitro evaluation.
Lab. Invest.
2008;88;9
Aberrant Notch3 and Notch4 expression in human hepatocellular carcinoma.
Liver Int.
2007;27;7

Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas.
Cancer Cell
2007;12;3

Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma.
Cancer Res.
2007;67;13
Notch3 intracellular domain accumulates in HepG2 cell line.
Anticancer Res.
2006;26;3A
GADD45-alpha expression in cirrhosis and hepatocellular carcinoma: relationship with DNA repair and proliferation.
Hum. Pathol.
2005;36;11
[ See timeline ] [ See all publications ]
means that Gramantieri, Laura has 17 papers cited a least 17 times - methodology
Center for Applied Biomedical Research (CRBA), S.Orsola-Malpighi University Hospital, Bologna, Italy.
Due mainly to homonyms, errors are possible and if you detect "false positives" or "false negatives" don't be too frustrated and please contact the webmaster.